Several analysts are expecting the stocks of FGEN to post sales close to $92.65 million for the current quarter according to reports. Five of the investment analysts have already provided estimates for the earnings generated by this company, with the highest-earning coming in at around $118.50 million, and the lowest fixed at $58 million. The company reported a meager amount of sales the previous year, accruing just $7.97 million, which should be indicative of an annual growth rate of around 1062.5%. The company will be issuing its next earnings result on the 1st of March.
The Quarterly Earnings of FGEN
The company posted their previous earnings result on the 5th of November. FGEN had posted an EPS of $0.35 for this quarter, which was met with stiff competition by the consensus estimate of $0.80. The company also earned a revenue of around $44.03 million, which could be compared to the analyst estimate of $61.49 million. The company’s net margin stands at a negative 191.78% with a return on its equity fixed at a negative 48.19%.
There have been quite a few research equities that have commented on the stocks of FGEN. SVB Leerink has already boosted the price target on the shares of this company from $90 to $92 while giving the company a rating of outperform in a research note last Friday. Raymond James has also set a rating of underperform for the company, which they published in a 26th October research report. Zacks Investment Research has also lowered the rating of the company from buy to hold, in an 11th November research note. In the end, ValuEngine also raised the shares of the company from a rating of hold, to a rating of buy, in a research note that was published on the 1st of December.
Two of the analysts have already given the company a rating sell, while three of them have given it a rating of hold. Four analysts have given the stocks of this firm a rating of buy. Currently, FGEN enjoys a consensus rating of hold, with a price target of $58.
